Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI. But doctors are unclear about the optimal antithrombotic therapy to prescribe after procedure to prevent clotting, and new research suggests a possible alternative, according to a study presented today at the American College of Cardiology's 55th Annual Scientific Session. ACC.06 is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine.
Previous research has shown that adding the antithrombotic drug abciximab, (a glycoprotein IIb/IIIa receptor inhibitor) to therapy with ticlopidine plus aspirin significantly reduces post-stent implantation complications, including death, repeat heart attack or reintervention. The drug ticlopidine has been replaced by clopidogrel in recent research, which is safe and acts more rapidly in a 600 mg dosage level, offering better platelet inhibition within two hours of administration.
In a previous trial of low-to-moderate risk patients, the use of clopidogrel was associated with such a low frequency of early complications that the use of abciximab offered no clinical benefit. However, higher risk patients with ACS may benefit from a more potent antithrombotic regimen. The ISAR-REACT 2 trial evaluated for the first time the value of abciximab in patients with ACS undergoing PCI after pretreatment with 600 mg of clopidogrel.
"No specifically designed randomized studies have previously been conducted on the value of abciximab plus a high-dose of clopidogrel during PCI in ACS patients," said Adnan Kastrati, M.D., of the Deutscshes Herzzentrum Munich, Germany and lead author of the study. "Together with other current trials, this will help to define the current optimal adjunct antithrombotic therapy in patients with ACS managed with PCI."
ThPage: 1 2 Related medicine news :1
. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD2
. Internal medicine organizations survey internists on maintenance of certification3
. ASH Self-Assessment Program receives approval for maintenance of certification credit4
. Future therapies for stroke may block cell death5
. Antifolate therapies found effective against certain type of malaria6
. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer7
. A sweet step toward new cancer therapies8
. Psychological therapies for common anxiety disorder not readily available in primary care settings9
. About 5 percent of adults with insomnia use alternative therapies10
. Combined therapies may boost immune response and long-term protection against brain tumors11
. New hope in cancer vaccines emerges as novel therapies are developed and tested